Cambridge-based City Therapeutics raised $200 million in its IPO to fund its work on next-generation RNA interference (RNAi) medicines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results